Astellas Pharma Other Current Assets

As of the most recent data (June 2026), ALPMY shows a other current assets of $58B. That compares with $100B in the prior-year period — down 44.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ALPMY's other current assets is now $58B (was $100B) — a 44.1% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Astellas Pharma is outperforming or lagging.

Tracking ALPMY's other current assets over time shows whether Astellas Pharma is scaling, shrinking, or reshaping that part of the business. The current reading is $58B That compares with $100B in the prior-year period — down 44.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other current assets page, Stockcircle has Astellas Pharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other current assets (currently $58B) with ownership activity and broader fundamentals.

Astellas Pharma's other current assets is $58B; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.